Temodar — CareFirst (Caremark)
Central nervous system (CNS) cancer
Initial criteria
- Authorization may be granted for treatment of CNS cancers.
Reauthorization criteria
- Authorization may be renewed if there is no evidence of unacceptable toxicity or disease progression while on the current regimen.
Approval duration
12 months